The recent FDA approval of teclistamab for R/R multiple myeloma Published 2022-10-28 Download video MP4 360p Recommendations 02:57 LINKER-MM1: promising safety and efficacy of linvoseltamab in R/R MM 03:53 Mutational Burden in Patients with Treatment-Naïve CLL 01:54 Brexu-cel in the treatment of R/R MCL: insights from the ZUMA-2 and ZUMA-18 trials 03:16 CD-7 targeted CAR-T therapy in heavily pretreated patients with AML: a Phase I trial 03:10 The potential for early identification of relapse in DLBCL using serial ctDNA sampling 03:59 Single-cell transcriptomic analysis of B-ALL: leukemia cell state and genetic alterations 01:23 Asparaginase formulations in ALL treatment: products available and their side effect profiles 01:56 Copanlisib, rituximab, & bendamustine in transplant-ineligible R/R DLBCL 01:33 Prognostic impact of WT1 mutations in newly diagnosed and R/R AML 01:04 The challenge of treating HMA-refractory MDS patients 04:02 ELM-2: promising safety and efficacy of odronextamab in R/R DLBCL 01:05 Hematological predictors of thrombotic risk or disease progression in essential thrombocythemia 02:50 Time to achieve platelet count response with efgartigimod in patients with persistent/chronic ITP 02:05 RADAR: guiding treatment for NDMM with MRD and genetic risk 03:34 ITP Fatigue Animation 01:23 Decitabine, venetoclax, and IDH inhibitor in IDH-mutated AML 01:58 Manipulating immune targeting of solid tumors with gene therapy 01:35 IPSS-M: prognostic power in HMA-treated MDS patients 02:25 OxCOM: monitoring monoclonal gammopathies for progression to active myeloma 00:29 Interferon-γ signaling contributes to drug resistance in AML Similar videos 02:04 Approval of teclistamab in triple-class refractory multiple myeloma 06:48 Alfred Garfall: Evaluating Teclistamab in Relapsed and/or Refractory Multiple Myeloma 22:21 TECVAYLI (Teclistamab) Everything You Need to Know 08:12 Evaluating Teclistamab in Relapsed and/or Refractory Multiple Myeloma 05:38 Teclistamab for R/R myeloma 14:31 Teclistamab - Guest Lecture 01:15 Safety & efficacy of bispecific antibodies in multiple myeloma: teclistamab & elranatamb 01:46 How Teclistamab Treatment Affects Quality of Life | Rakesh Popat, MD | EHA 2022 49:38 Off-the-shelf Immune Drug for Aggressive Multiple Myeloma: Teclistamab 05:41 Efficacy of Teclistimab versus current treatments in patients with triple-class exposed RR myeloma 17:55 Talquetamab | Therapies on the horizon 04:13 Teclistamab + Daratumumab Is Well Tolerated in Relapsed/Refractory Multiple Myeloma Patients 02:43 Updated results from MajesTEC-1 1:05:39 IMWG Conference Series: ASCO & EHA 2023 07:25 Updated data: Phase 1/2 MajesTEC-1 study evaluating teclistamab, a BCMA x CD3 bispecific antibody 01:52 Impact of prior BCMA-directed therapy on the efficacy of elranatamab in R/R multiple myeloma 03:44 What should myeloma patients know about talquetamab? 2:50:58 IMF Patient & Family Webinar - Back to Basics: From Testing to Tailored Therapy 47:35 Top Doctor & Patient Talk Game Changing Cancer Treatments: How Close is a Cure? (Multiple Myeloma) 19:37 Bispecific Monoclonal Antibodies and CAR T-Cell Therapy in Multiple Myeloma, Omar Nadeem, MD More results